- 作者：Michel Farnier ; John R. Guyton ; Erin Jensen ; Adam B. Polis ; Amy O. Johnson-Levonas ; Philippe Brudi
- 关键词：Simvastatin ; Ezetimibe ; Correlation ; Lipoprotein ; Apolipoprotein B
- 刊名：Atherosclerosis
- 出版年：2013
- 出版时间：August, 2013
- 年：2013
- 卷：229
- 期：2
- 页码：415-422
- 全文大小：443 K
Background/synopsis
Apolipoprotein (apo) B is highly predictive of coronary risk, especially in patients with high triglycerides (TG). This post hoc analysis evaluated the effects of lipid-lowering therapy on correlations between apoB and low-density lipoprotein cholesterol (apoB:LDL-C) and non-high-density lipoprotein cholesterol (apoB:non-HDL-C) in patients with TG< and ¡Ý200?mg/dL.Methods
This analysis used data from 3 randomized clinical trials in patients with primary hypercholesterolemia receiving placebo, ezetimibe (EZE), simvastatin (SIMVA) or EZE/SIMVA for 12 weeks. Simple?linear regression analyses predicted LDL-C and non-HDL-C levels corresponding to apoB values (80?mg/dL) at baseline and Week 12.
Results
ApoB correlated with LDL-C (r?¡Ý?0.76) and non-HDL-C (r?¡Ý?0.86) at baseline. The correlations were strengthened with SIMVA and EZE/SIMVA at Week 12 (r?¡Ý?0.88 for LDL-C and r?¡Ý?0.94 for non-HDL-C). The predicted LDL-C and non-HDL-C values were lower following treatment with SIMVA or EZE/SIMVA than for placebo and EZE. For SIMVA and EZE/SIMVA, the predicted LDL-C and non-HDL-C values were closer to more aggressive LDL-C and non-HDL-C levels (i.e., 70 and 100?mg/dL, respectively). The apoB:LDL-C and apoB:non-HDL-C correlations were weaker and the predicted LDL-C values were generally lower in high TG patients than in low TG patients both at baseline and Week 12. In contrast, the predicted non-HDL-C values were generally higher in high versus low TG patients at baseline but less so at Week 12.
Conclusion
After treatment with EZE, SIMVA, or EZE/SIMVA, a given apoB value corresponds to lower LDL-C and non-HDL-C levels than those obtained from untreated patients.